Loading…
COSENTYX is a brand name for Secukinumab, supplied as a powder for solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Verbatim from this product's HC label. Tap a section to expand.
4 Geriatrics 2024-04 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ..........................................................................................
2 TABLE OF CONTENTS ............................................................................................................ 2 Part 1: Health Professional Information ................................................................................
5 1. Indications ................................................................................................................ 1 Pediatrics................................................................................................................
2 Geriatrics ................................................................................................................ 6 2. Contraindications ......................................................................................................
6 4. Dosage and Administration ....................................................................................... 1 Dosing Considerations ...........................................................................................
2 Recommended Dose and Dosage Adjustment ...................................................... 3 Reconstitution ........................................................................................................ 4 Administration .......................................................................................................
5 Missed Dose ........................................................................................................... 8 5. Overdose ..................................................................................................................
9 6. Dosage Forms, Strengths, Composition and Packaging ............................................... 9 7. Warnings and Precautions ....................................................................................... 10 Carcinogenesis and Genotoxicity .....................................................................................
10 Gastrointestinal................................................................................................................ 11 Immune ............................................................................................................................
11 Reproductive Health ........................................................................................................ 12 Sensitivity/Resistance ......................................................................................................
12 COSENTYX® (secukinumab injection/secukinumab for injection) - Product Monograph Page 3 of 100 Skin ...................................................................................................................................
4 Geriatrics 2024-04 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ..........................................................................................
2 TABLE OF CONTENTS ............................................................................................................ 2 Part 1: Health Professional Information ................................................................................
5 1. Indications ................................................................................................................ 1 Pediatrics................................................................................................................
2 Geriatrics ................................................................................................................ 6 2. Contraindications ......................................................................................................
6 4. Dosage and Administration ....................................................................................... 1 Dosing Considerations ...........................................................................................
2 Recommended Dose and Dosage Adjustment ...................................................... 3 Reconstitution ........................................................................................................ 4 Administration .......................................................................................................
5 Missed Dose ........................................................................................................... 8 5. Overdose ..................................................................................................................
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
1 Special Populations .............................................................................................. 1 Pregnancy.........................................................................................................
2 Breastfeeding ................................................................................................... 3 Pediatrics..........................................................................................................
4 Geriatrics .......................................................................................................... 13 8. Adverse Reactions ...................................................................................................
1 Adverse Reaction Overview ................................................................................. 2 Clinical Trial Adverse Reactions ........................................................................... 3 Less Common Clinical Trial Adverse Reactions ....................................................
5 Post-Market Adverse Reactions........................................................................... 21 9. Drug Interactions .................................................................................................... 2 Drug Interactions Overview .................................................................................
5 Drug-Food Interactions ........................................................................................ 6 Drug-Herb Interactions ........................................................................................ 7 Drug-Laboratory Test Interactions.......................................................................
22 10. Clinical Pharmacology ............................................................................................. 1 Mechanism of Action ...........................................................................................
2 Pharmacodynamics .............................................................................................. 3 Pharmacokinetics ................................................................................................. 23 11.
Storage, Stability and Disposal................................................................................. 25 12. Special Handling Instructions ...................................................................................
25 Part 2 : Scientific Information ............................................................................................. 26 13. Pharmaceutical Information ....................................................................................
26 14. Clinical Trials […]
9 6. Dosage Forms, Strengths, Composition and Packaging ............................................... 9 7. Warnings and Precautions ....................................................................................... 10 Carcinogenesis and Genotoxicity .....................................................................................
10 Gastrointestinal................................................................................................................ 11 Immune ............................................................................................................................
11 Reproductive Health ........................................................................................................ 12 Sensitivity/Resistance ......................................................................................................
12 COSENTYX® (secukinumab injection/secukinumab for injection) - Product Monograph Page 3 of 100 Skin ...................................................................................................................................
1 Special Populations .............................................................................................. 1 Pregnancy.........................................................................................................
2 Breastfeeding ................................................................................................... 3 Pediatrics..........................................................................................................
4 Geriatrics .......................................................................................................... 13 8. Adverse Reactions ...................................................................................................
1 Adverse Reaction Overview ................................................................................. 2 Clinical Trial Adverse Reactions ........................................................................... 3 Less Common Clinical Trial Adverse Reactions ....................................................
5 Post-Market Adverse Reactions........................................................................... 21 9. Drug Interactions .................................................................................................... 2 Drug Interactions Overview .................................................................................
5 Drug-Food Interactions ........................................................................................ 6 Drug-Herb Interactions ........................................................................................ 7 Drug-Laboratory Test Interactions.......................................................................
22 10. Clinical Pharmacology ............................................................................................. 1 Mechanism of Action ...........................................................................................
2 Pharmacodynamics .............................................................................................. 3 Pharmacokinetics ................................................................................................. 23 11.
Storage, Stability and Disposal................................................................................. 25 12. Special Handling Instructions ...................................................................................
25 Part 2 : Scientific Information ............................................................................................. 26 13. Pharmaceutical Information ....................................................................................
26 14. Clinical Trials ........................................................................................................... 1 Clinical Trials by Indication […]